10-Q quarterly report · filed Nov 3, 2026

IDEAYA Biosciences, Inc. (IDYA) Q3 2026 10-Q Quarterly Report

Short answer

IDEAYA Biosciences, Inc. (IDYA) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $10M (down 95.1% year over year) with net income of −$126M.

Q3 2026 key financials · XBRL

Revenue
$10M
−95.1% YoY · +15.6% QoQ
Net income
−$126M
−205.5% YoY · −11.8% QoQ
Operating margin
-1343.7%
EPS (diluted)
−$1.23
−191.1% YoY · −0.8% QoQ

Source: XBRL data from the IDEAYA Biosciences, Inc. (IDYA) Q3 2026 10-Q on SEC EDGAR. USD.

IDEAYA Biosciences, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly collaboration revenue $10.2M, up 16% from $8.9M in Q2 2026
  • Q3 net loss $125.7M, operating loss $137.6M, no product revenue
  • Darovasertib highest Q3 clinical spend $35.1M, IDE161 lowest at $1.4M
  • Cash, equivalents and marketable securities approximately $1.15B; operating cash used $256.9M
  • Financing cash $364.1M, including $323.4M net follow-on offering proceeds; funding expected for at least twelve months

Risk Factors

  • No material changes to risk factors disclosed in the February 17, 2026 Annual Report
  • Carried-forward risks include potential adverse effects on business, financial condition, and future results
  • Quarterly filing provides no newly triggered regulatory, operational, competitive, or financial risk વિગતો

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other IDEAYA Biosciences, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.